TORONTO, July 29, 2015 /PRNewswire/ - Concordia Healthcare Corp. ("Concordia" or "the Company") (NASDAQ: CXRX) (TSX: CXR), today announced it will release its second quarter 2015 financial results after market close on Thursday, August 13, 2015.

The Company will subsequently hold a conference call on Friday, August 14, 2015, at 8:30 a.m. ET hosted by Mr. Mark Thompson, Chairman and Chief Executive Officer, Mr. Adrian de Saldanha, Chief Financial Officer, and Mr. Wayne Kreppner, President and Chief Operating Officer. A question-and-answer session will follow the corporate update.

This call is being webcast and can be accessed from the Concordia website at www.concordiarx.com or by going to:

http://event.on24.com/r.htm?e=1028822&s=1&k=FE8E5E6629D5B5CFD275FA284F328C7A

An archived replay of the webcast will be available for 90 days.

About Concordia

Concordia is a diverse healthcare company focused on legacy pharmaceutical products and orphan drugs. Concordia's legacy pharmaceutical division, Concordia Pharmaceuticals Inc., consists of a portfolio of branded products and authorized generic contracts, including branded products such as Nilandron®, for the treatment of metastatic prostate cancer; Dibenzyline®, for the treatment of pheochromocytoma; Lanoxin®, for the treatment of mild-to-moderate heart failure and atrial fibrillation; Plaquenil®, for the treatment of lupus and rheumatoid arthritis, Donnatal® for the treatment of irritable bowel syndrome and Zonegran® (zonisamide) for treatment of partial seizures in adults with epilepsy. Concordia's orphan drugs division, Concordia Laboratories Inc., owns Photofrin®. Photofrin® is marketed by Pinnacle Biologics, Inc. in the United States.

Concordia operates out of facilities in Oakville, Ontario; Bridgetown, Barbados; Roanoke, Virginia and has a specialty healthcare distribution (SHD) division that operates out of Kansas City, Missouri. Pinnacle Biologics Inc. is located in Chicago, Illinois.

SOURCE Concordia Healthcare Corp.